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1. Introduction 
Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) 
are a global health crisis of unprecedented dimensions, causing  over 25 million deaths 
worldwide since it was first recognized as a disease entity in the early 1980s.(Joint United 
Nations Program on HIV/AIDS 2008)  In 2008 alone, there were approximately 2.7 million 
newly infected and over 33 million persons living with HIV globally, of whom between 1.8 
and 2.3 million died.(Joint United Nations Program on HIV/AIDS 2011) In the 24 years 
since zidovudine was approved for the treatment of HIV infection, remarkable advances 
have been made in the understanding of disease pathogenesis and translating that 
knowledge into practical therapeutics. Most notably, the advent of highly active 
antiretroviral therapy (HAART) has transformed HIV from an inevitably fatal disease to one 
that, if managed appropriately, can be considered a chronic condition. As a result, the 
overall number of people living with HIV is increasing as these regimens extend life and as 
new infections outnumber AIDS deaths. (www.unaids.org; Joint United Nations Program 
on HIV/AIDS 2011)  
The number of HIV treatment regimens has grown exponentially, particularly in the past 
decade. This, coupled with advances in the understanding of disease pathogenesis and 
progression, has made HIV disease management among the most dynamic fields in modern 
medicine. A number of guidelines have been developed to assist practitioners with often 
complex treatment decisions. These include the 2010 International AIDS Society (IAS/IAS-
USA) guidelines and the 2011 US Department of Health and Human Services (DHHS) HIV 
treatment guidelines.(Thompson, et al., 2010; http//:www.aidsinfo.nih.gov; Thompson, et 
al., 2010; United States Department of Health and Human Services (US DHHS) Panel on 
Antiretroviral Guidelines for Adults and Adolescents 2011)  
Close to 30 individual drugs and fixed-dose combinations are available to treat HIV. Despite 
the availability of a broad range of individual antiretroviral treatments and combinations, 
drug resistance remains a common phenomenon, and treatment failure is still frequently 
observed. Moreover, treatment advances—together with recent demographic shifts—have 
resulted in a dramatic expansion in the population of treatment-experienced patients. This 
group comprises an ever-increasing proportion of the patients whom HIV clinicians are 
called upon to treat. This review attempts to integrate guideline recommendations and 
evidence from recent clinical trials to identify best practices in the management of these 
patients. 
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2. The treatment-experienced patient 
According to the IAS, the primary goal of antiretroviral therapy is to increase disease-free 
survival through the maximal suppression of viral replication and preservation of 
immunologic function.(Thompson, et al., 2010; Hammer, et al., 2008)  Optimal therapy for 
patients with HIV depends on carefully balancing these benefits with the risks for drug 
toxicity, potential emergence of viral resistance, and the understanding that HIV infection is 
a chronic disease that requires continuous therapy—often for decades. These considerations 
are complicated in the treatment-experienced patient, as these patients often have 
accumulated resistance mutations to a number of drugs in existing antiretroviral drug 
classes.  Modifications of treatment regimens may be forced by undue toxicity, drug-drug 
interactions, or outright virologic failure.  While, theoretically, it is optimal for patients to 
remain on a single treatment until virologic failure, regimens may also be modified to 
improve convenience and/or ameliorate minor or cosmetic side effects, ultimately 
improving adherence and increasing time to virologic failure.(Thompson, et al., 2010; 
Hammer, et al. 2008) 
3. Defining treatment failure 
Treatment failure may be defined based on HIV RNA response to therapy (virologic failure), 
changes in CD4+ cell count (immunologic failure), and the occurrence or recurrence of HIV-
related events after ≥ 3 months on an antiretroviral regimen (clinical progression). (US 
Department of Health and Human Services (DHHS) Panel on Antiretroviral treatment 
guidelines for adults and adolescents 2011, http://aidsinfor.nih.gov) 
Virologic failure may be characterized as persistent HIV RNA viral load above 200 
copies/mL. (US DHHS HIV treatment guidelines 2011)  Occasional episodes of viral 
detection between 51 and 1000 copies/mL may occur due to laboratory variation or other 
transient viral illness. However, frequent and/or consistent viremia is a strong indicator of 
treatment failure and must be addressed to prevent selection of drug-resistant virus. 
Immunologic failure is the failure to achieve and maintain an adequate CD4+ T-cell 
response despite virologic suppression. Although an absolute definition has not been agreed 
upon by experts, immunologic failure can generally be considered as failure to increase 
CD4+ cell counts above 350−500 cells/mm3 over 4−7 years of treatment.(US DHHS HIV 
treatment guidelines 2011)  Alternatively, it may be defined as failure to increase CD4+ cell 
count by 50−100 cells/mm3 above baseline during the first year of a new therapy, or a 
decline in CD4+ cell count to below baseline while on therapy.(US DHHS HIV treatment 
guidelines 2011) 
Clinical progression is the occurrence or recurrence of HIV-related conditions (a new AIDS 
defining illness or death) after ≥3 months of HAART, excluding immune reconstitution 
syndromes.(US DHHS HIV treatment guidelines 2011)  
While virologic failure, immunologic failure, and clinical progression are closely related, 
all three may not occur simultaneously. In general, virologic failure precedes 
immunologic failure and clinical progression of disease; however, the period between 
overt virologic failure and detectable suppression of CD4+ cell count and/or HIV-related 
events can span from months to years.(US DHHS HIV treatment guidelines 2011; Deeks, 
et al., AIDS 2002)   
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4. Assessing treatment failure 
In general, treatment failure cannot be attributed to any single cause. When assessing 
individual patients with treatment failure, it is important to recognize that multiple reasons 
for failure may occur in a single patient. These include:   
1. patient-specific factors, such as earlier calendar year of starting therapy, high baseline 
HIV RNA level, lower nadir CD4+ cell count, prior AIDS diagnosis, the presence of 
comorbidities such as depression or active substance use, and infection with a drug-
resistant virus; 
2. medication noncompliance and/or missed clinic appointments; 
3. medication side effects and toxicity, potentially leading to noncompliance; 
4. suboptimal pharmacokinetics, including variable absorption, metabolism, penetration, 
food/fasting requirements, and drug and natural product interactions; and 
5. suboptimal potency of the antiretroviral regimen.(http://aidsinfo.nih.gov) 
Of these reasons, suboptimal adherence and toxicities account for the majority (26%−64%) of 
treatment failures and discontinuations.(d’Arminio Monforte, et al. AIDS 2000; Mocroft A, et 
al. AIDS 2001)  
5. Addressing treatment failure 
Careful assessment of the reasons for treatment failure is critical, as approaches to 
subsequent therapy differ based on the combination of risk factors in the individual patient. 
Of the potential reasons for failure summarized above, all except certain patient-specific risk 
factors can be addressed through appropriate attention to maintaining adherence (either to 
the current regimen or to a new regimen) and careful assessment of all of the patients’ 
current medications, including but not limited to HAART, treatments for comorbid 
conditions, and natural health products. 
5.1 Noncompliance 
Unless the patient was infected with resistant virus, treatment failure implies inadequate 
adherence to antiretroviral therapy. The development of drug resistance requires concurrent 
antiretroviral drug exposure and ongoing viral replication. Thus, even intermediate 
adherence (e.g., 70%−90% compliance) is associated with considerable risk for the 
development of drug-resistant strains of HIV, as a result of ongoing low-level drug 
exposure and intermittent viral replication. (Lucas GM, et al., J Antimicrob Chemother 2005)  
For this reason, it is worthwhile to target 90%−100% compliance in patients with HIV. 
The causes of nonadherence must be identified and addressed in cooperation with the 
patient to avoid future treatment failures and the accumulation of drug-resistance 
mutations. Numerous reasons for nonadherence to medication have been described in the 
literature. These include, but are not limited to, regimen complexity (a particular problem in 
HIV treatment), (Ammassari, et al., Neurology 2003) side effects, (Ammassari, et al., JAIDS 
2001) failure to understand dosing directions, illiteracy,(Kalichman, et al., J Natl Med Assoc 
1999) substance abuse, (Power , et al., AIDS Pt Care STDS 2003)  psychological issues, 
(Gibbie, et al., Sex Health 2007) cost, missed appointments, and lack of social supports.. 
Routinely discussing adherence with patients at each visit may improve medication 
adherence. Pill boxes are helpful for patients who are busy or forgetful and have the 
additional benefit of being highly cost-effective. In one study, its use resulted in a significant 
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4% improvement in adherence that correlated with a significant reduction in viral load. 
(Petersen M, et al. CROI 2007) 
5.2 Side effects and toxicities 
When treatment fails, the patient should be carefully assessed for side effects and their 
duration and severity. In some cases, side effects are transiently associated with the 
initiation of a new regimen. However, ongoing side effects should first be managed, if 
possible, by using symptomatic treatment (e.g., antiemetics and antidiarrheals). 
Alternatively, substitution of one drug for another in the same therapeutic class may reduce 
symptoms. For example, tenofovir or abacavir may be used to replace zidovudine in 
patients with gastrointestinal symptoms or anemia.(US DHHS HIV treatment guidelines 
2011)  Changing drug classes altogether is also an option in patients who experience side 
effects with multiple alternative drugs within the same class. 
5.3 Pharmacokinetic parameters 
The risk for treatment failure is increased if the patient is not taking the medication correctly 
(e.g., with or without food and otherwise, as directed). Similarly, treatment may fail if the 
patient is taking other medications, prescription or over the counter, that may affect drug 
absorption or metabolism (e.g., proton pump inhibitors).  
The effect of natural health products, such as herbs and vitamins, is underappreciated as a 
source of potentially detrimental interactions with antiretroviral treatment. Data suggest 
that more than two thirds of HIV patients take natural or alternative health products, 
(Rivera, et al., J Natl Med Assoc 2005) and that many physicians are not aware of their 
patients’ use of  “natural” or alternative health products. The complexities of accounting for 
interactions between these products and antiretroviral treatments are compounded by the 
fact that natural health products are not produced to a generally accepted standard, and 
there may be wide variability in potency between and within brands. Moreover, many 
natural health products are complex mixtures that may contain components that influence 
drug metabolizing enzymes and drug transporters.(Lee LS, et al. CID 2006)  Table 1 presents 
some known interactions between antiretroviral drugs and natural health products. 
5.4 Drug resistance 
When noncompliance, side effects and toxicities, and potential pharmacokinetic interactions 
have been excluded, drug resistance should be considered. Resistance testing should be 
performed while the patient is still on the failing regimen or within 4 weeks of 
discontinuation, and before starting a new regimen. In general, changing therapy for 
virologic failure is warranted for detectable viremia >1000 copies/mL. Some authorities 
suggest a more aggressive approach, in which therapy is changed for any repeated, 
detectable viremia (e.g., two consecutive HIV RNA >50 copies/mL after suppression to <50 
copies/mL in a patient receiving antiretroviral treatment), but this is not routine 
practice.(http://aidsinfo.nih.gov) 
5.4.1 Drug resistance testing 
Resistance testing may be accomplished through genotype or phenotype testing. Two types 
of resistance assays are available in clinical practice. Genotypic assays involve sequencing 
HIV-1 genes to detect mutations that confer HIV-1 drug resistance, whereas phenotypic 
assays use cell-culture based viral replication assays in the presence and absence of drugs. 
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 St. John’s wort Echinacea Milk thistle Garlic Vitamin E 
PIs 
Should not be 
coadminister-
ed; may cause 
significant 
decrease in PI 
levels 
Possible 
interaction; 
echinacea 
may interact 
with ARVs 
that are CYP 
3A4 or CYP 
2C9 substrates
Possible 
interaction, 
except for 
indinavir; milk 
thistle may 
inhibit 
CYP3A4  
Possible 
interaction; 
garlic may 
inhibit CYP3A4
 
GI toxicity has 
been reported 
with 
coadministra-
tion of garlic 
and ritonavir 
Should not be 
coadministered 
with 
tipranavir/rito
navir; may 
increase the 
risk of bleeding 
NNRTIs 
Should not be 
coadminister-
ed; may cause 
significant 
decrease in 
NNRTI levels 
(including 
etravirine) 
Possible 
interaction; 
echinacea 
may interact 
with ARVs 
that are CYP 
3A4 or CYP 
2C9 substrates
Possible 
interaction; 
milk thistle 
may inhibit 
CYP 3A4  
Possible 
interaction; 
garlic may 
inhibit CYP 3A4 
Unknown  
NRTIs 
No evidence 
for interaction
No evidence 
for interaction 
No evidence 
for interaction
No evidence for 
interaction 
No evidence 
for interaction 
Integrase 
inhibitor 
(raltegravir) 
No evidence 
for interaction
No evidence 
for interaction
No evidence 
for interaction
No evidence for 
interaction 
No evidence 
for interaction 
CCR5 
antagonist 
(maraviroc) 
Coadministra-
tion not 
recommended
; expected to 
decrease 
maraviroc 
concentrations 
Possible 
interaction; 
echinacea 
may interact 
with ARVs 
that are CYP 
3A4 and CYP 
2C9 substrates 
Possible 
interaction; 
milk thistle 
may inhibit 
CYP 3A4  
Possible 
interaction; 
garlic may 
inhibit CYP 3A4 
No evidence 
for interaction 
Table 1. Known Interactions Between Antiretroviral (ARV) Therapies and Natural Health 
Products 
CYP, cytochrome P; GI, gastrointestinal; NNRTI, non-nucleoside reverse transcriptase 
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.  
(Reyataz,  Intelence, Aptivus, & Selzentry package inserts; Gorski, et al., 2004; Mills, et al., 
2005; Venkataramanan, et al.,  2000; Foster, et al.,  2001; Laroche,  et al., 1998; Lee, et al., 2006) 
Both tests can accurately identify resistance only in the predominant virus in patients, so a 
substantial proportion of the circulating virus may be resistant even in patients with negative 
results.(Schuurman, et al., J Clin Microbiol 1999)  Furthermore, drug resistance testing is 
limited, because it does not predict the activity of antiretroviral agents when used in 
combination and requires a viral load >1000. Also, it only reveals resistance based on drug 
pressure, so it is important to consider all prior genotype tests, as these mutations will remain, 
even if not currently detectable. In addition to these methods, “virtual phenotyping” utilizes 
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genotype data to evaluate in vitro drug susceptibility of the virus; for most antiretroviral 
agents, this test predicts actual phenotypic resistance.(Perez-Elias, et al., Antivir Ther 2003)  
Despite limitations, the preponderance of evidence suggests an advantage for the use of 
genotypic testing over standard of care in the selection of regimens for patients with 
treatment failure.(Hirsch, et al., CID 2003)  Compared with standard of care, the patients 
allocated to the genotyping arms of these studies had substantially greater decreases in 
plasma HIV RNA levels and were more likely to achieve undetectable HIV RNA levels. In 
contrast, trials of phenotypic testing versus standard of care have not produced such clear-
cut results, with variable outcomes in different studies. (Hirsch, CID 2003; Melnick, et al., 
abstract #786 CROI 2000; Cohen, et al., AIDS 2002; Torti, et al., CID 2005; Dunn, et al., 
JAIDS, 2005; Vray, et al.,  2003;  Wegner, et al., CID 2004). A recent clinical study compared 
outcomes in patients randomly assigned to either genotypic testing or genotypic plus virtual 
phenotypic testing. (Hales, et al, PLoS Clin Trials 2006)  After 48 weeks, no significant 
differences were observed between the two groups in terms of mean change from baseline 
plasma HIV RNA and mean change from baseline CD4+ cell count, suggesting that 
resistance testing with genotyping alone is sufficient for the management of HIV infection. 
Tables 2, 3, and 4 indicate resistance mutations for the three major classes of antiretrovirals.  
6. 2011 Guidelines for the management of treatment-experienced patients 
When selecting appropriate treatment, all resistance testing should be considered, as should 
the patient’s treatment history, comorbidities, concomitant medications, and prior 
intolerance. Treatment should be individualized based on these factors. 
In patients with limited prior treatment but with no resistance, the potential for 
nonadherence should be evaluated and strongly considered. Resumption of the same 
regimen or initiation of a new regimen should be considered, with genotypic testing within 
4 - 6 weeks to determine whether a resistant viral strain emerges if viral suppression cannot 
be achieved. In patients with limited prior treatment who are receiving protease inhibitors 
(PIs), thought should be given to intensifying one drug or boosting. The primary goal of 
therapy is to resuppress HIV RNA levels to undetectable levels and to prevent further 
selection of resistance mutations. (http://aidsinfo.nih.gov) 
In patients with limited prior treatment and recognized drug resistance, maximal HIV RNA 
suppression (e.g., to <50 copies/mL) is required to prevent the selection of additional 
resistance mutations. (Thompson, et al, 2010; http://aidsinfo.nih.gov) Changes in the 
treatment regimen should be considered to minimize selection of resistance mutations. New 
regimens should include ≥2 active agents. (Thompson, et al, 2010; http://aidsinfo.nih.gov) 
Resistance mutations for nucleoside analog reverse transcriptase inhibitors (NRTIs), non-
NRTIs (NNRTIs), and PIs are noted in Tables 2, 3, and 4, respectively. Effects of Protease 
mutations are noted in Table 5. 
In patients with extensive prior treatment and drug resistance, maximal viral suppression is 
warranted to prevent the accumulation of additional resistance mutations. Antiretroviral 
drugs from newer classes should be considered. If viral suppression is impossible to 
achieve, the primary goal is to preserve immunologic function and prevent clinical 
progression. When a new regimen with two fully active agents cannot be identified, it is 
reasonable to observe the patient on the same regimen rather than changing the regimen, 
depending on the stage of HIV disease. (Thompson, et al, 2010; http://aidsinfo.nih.gov) 
Patients with significant treatment experience and drug-resistant virus can often still achieve 
undetectable viral loads and the goal is still to reestablish suppression of the virus.  
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NRTI 
Resistance mutations 
(IAS-USA) 
Mutations 
associated with 
reduced RC 
All currently approved 
NRTIs 
69 insertion complex: M41L, A62V, 69 
insert, K70R, L210W, T215Y/F, K219Q/E
 
All currently approved 
NRTIs except tenofovir
151 complex: A62V, V75I, F77L, F116Y, 
Q151M
Q151M 
All currently approved 
NRTIs 
Thymidine analogue-associated 
mutations (TAMs): M41L, D67N, K70R, 
L210W, T215Y/F, K219Q/E
 
Abacavir K65R, L74V, Y115F, M184V K65R, M184V 
Didanosine K65R, L74V K65R
Emtricitabine K65R, M184V/I K65R, M184V 
Lamivudine K65R, M184V/I K65R, M184V 
Stavudine 
M41L, D67N, K70R, L210W, T215Y/F, 
K219O/E
 
Tenofovir K65R, K70E K65R
Zidovudine 
M41L, D67N, K70R, L10W, T215Y/F, 
K219Q/E
 
Table 2. NRTI resistance mutations  
IAS, International Aids Society; NRTI, nucleoside reverse transcriptase inhibitor; RC, 
replicative capacity. 
(Johnson, et al., 2009;  Garcia-Perez, et al., 2005; Girardet, et al., 2007; White, et al., 2002) 
 
NNRTI 
Resistance mutations 
(IAS-USA) 
Mutations associated with reduced RC 
Delavirdine 
K103N, V106M, Y181C, Y188L, 
P236L
V106A, G190C/S/E/Q/V/T, 
P225H, M230L, and P236L 
Efavirenz 
L100I, K103N, V106M, V108I, 
Y181C/I, Y188L, G190S/A, P225H
V106A, G190C/S/E/Q/V/T, 
P225H, M230L, and P236L 
Nevirapine 
L100I, K103N, V106A/M, V108I, 
Y181C/I, Y188C/L/H, G190A
V106A, G190C/S/E/Q/V/T, 
P225H, M230L, and P236L 
Table 3. NNRTI Resistance Mutations 
NNRTI, non-nucleoside reverse transcriptase inhibitor; RC, replicative capacity. 
(Johnson, et al., 2009; Archer, et al., 2000; Huang, et al., 2003; Wirden, et al., 2003) 
(US DHHS HIV management guidelines) NRTIs, in particular, have been shown to retain 
antiviral activity in patients with drug-resistant virus. Moreover, continued use of both NRTIs 
and PIs can select for drug-resistance mutations that reduce viral fitness. (Deeks, et al., 2005) 
If complete viral suppression is not feasible, the goals of treatment should be maintenance 
or improvement of CD4+ cell count and preventing clinical progression. Discontinuation is 
not recommended unless the patient has a high CD4+ count. Data suggest that partial 
virologic suppression of >0.5 to 1.0 log10 copies/mL below baseline is associated with 
clinical benefit; larger and more sustained reductions in HIV RNA are directly correlated 
with lower risk for disease progression. (Murray, et al., 1999)  In addition, a “holding 
regimen” will maintain poor viral fitness. For example, the M184V mutation, which 
increases resistance to lamivudine and emtricitabine, decreases viral fitness and increases 
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the antiviral activity of zidovudine, stavudine, and tenofovir. (Whitcomb, et al., 2003)  
Therefore, maintaining this resistance mutation by continuing lamivudine or emtricitabine 
can enhance the effect of zidovudine, stavudine, and/or tenofovir. (Wegner, et al., CID 2004) 
 
Protease inhibitor 
Major resistance mutations (IAS-
USA) 
Mutations associated with 
reduced RC 
Atazanavir +/- ritonavir I50L, I84V, N88S I50L 
Fosamprenavir/ritonavir I50V, I84V I50V, I84V 
Darunavir/ritonavir I47V, I50V, I54M/L, L76V, I84V  
Indinavir/ritonavir M46I/L, V82A/F/T, I84V  
Lopinavir/ritonavir 
V32I, I47V/A, L76V, 
V82A/F/T/S 
 
Nelfinavir D30N, L90M D30N, N88S, L90M 
Saquinavir/ritonavir G48V, L90M  
Tipranavir/ritonavir I47V, Q58E, T74P, V82L/T, I84V  
Table 4. Major Protease Inhibitor Resistance Mutations 
IAS, International Aids Society; RC, replicative capacity. 
(Johnson, et al., 2009; Archer, et al., 2000; Martinez-Picado, et al., 1999; Prado, et al., 2002; 
Resch, et al., 2002; Wirden, et al., 2003; Reyataz prescribing information) 
In some highly treatment-experienced patients, the addition of enfuvirtide should also be 
considered. In the T-20 versus Optimized Regimen Only (TORO) studies, adding 
enfuvirtide to an optimized background regimen was associated with significant 
antiretroviral and immunologic benefit in patients with >6 months of previous treatment 
with agents in three classes of antiretroviral drugs and/or resistance to drugs in these 
classes.(Lalezari, et al., 2003)  Notably, enfuvirtide is most effective when given with other 
active drugs. As shown in the TORO study, enfuvirtide monotherapy is associated with a 
high rate of emerging resistance. (Lalezari, et al., 2003) 
DHHS guidelines indicate no consensus on how to define or treat immunologic failure in 
the setting of a virologic response. (US DHHS HIV management guidelines)  Patients with 
discordant responses (e.g., undetectable HIV RNA but low CD4+ cell counts) should 
continue to receive their current treatment, unless they are taking zidovudine or didanosine, 
which have been shown to be myelosuppressive. However, time to immune response is 
variable and may even take years. In these cases, changing these drugs, if possible, is 
recommended. Additionally, changing trimethoprim-sulfamethoxazole prophylaxis to 
dapsone or aerosolized pentamidine may be warranted in this group in order to enhance 
immunologic response further. This should be considered prior to changing an 
antiretroviral regimen that is successfully suppressing viral load. 
7. Beyond the guidelines: Investigational therapeutic approaches 
Numerous permutations of various treatment strategies have been attempted. Below are 
several of the more commonly investigated therapeutic approaches. 
7.1 Structured treatment interruptions 
The CPCRA 064 study found that there was an increased risk of death, a long-term negative 
effect on CD4+ cell count, and no virologic or clinical benefit associated with a structured 
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treatment interruption.(Lawrence, et al., 2006) Based on these, it is advised to not 
discontinue an ARV regimen in an adherent patient except for in the presence of drug 
resistance and when awaiting genotype results. 
7.2 Double-boosted PIs 
Double-boosted PIs (two PIs plus ritonavir) may be clinically effective by increasing blood 
levels to the point where resistance is overcome.(Staszewski, et al., 2006)  This approach 
raises major issues, however,  in terms of drug interactions and may be suitable only for 
patients who have exhausted all other options. This is not strongly advised or recommended 
and the patient should be referred to an HIV specialist. 
7.3 Mega-HAART 
Multiple-drug rescue therapy (e.g., >5 antiretrovirals) has the complication of severe drug 
interactions. Thus, this is a last resort in highly selected patients and should be managed by 
an HIV specialist.(Montaner, et al., 2001) 
8. New treatment options 
Over the past 3 years, a number of new treatment options have been approved by the US 
Food and Drug Administration, including drugs from entirely new classes: maraviroc, a 
CCR5 antagonist, and raltegravir, an integrase inhibitor. Drug interactions of these newly 
approved agents are summarized in Table 6.  
 
Effect TPV LPV ATV DRV 
Decreased 
virologic 
response 
no firm data 6 or more 
mutations 
Increasing number 
of mutations 
I47V, I54M, T74P, 
I84V 
High level 
resistance 
no firm data 7 – 8 mutations; 
I47A, V32I; 
L76V+3 
mutations 
I50L, I84V, N88S 3+of: V11I, V32I, 
L33F, I47V, I50V 
I54M/L, G73S, 
L76V, I84V, L89V 
Possible 
increased 
virologic 
response 
L24I, I50L/V, 
F53Y/L/W, 
I54L, L76V 
 M46I + L76V 
without other 
mutations 
V82A 
Table 5. Impact of Protease Inhibitor Resistance Mutations: Effects of different PI mutations 
on different PIs 
*ATV, atazanavir; DRV, darunavir; LPV, lopinavir; TPV, tipranavir. PI, Protease Inhibitor 
(Norton, et al., 2008; DeMeyer, et al., 2009; Descamps, et al., 2009; Mo, et al., 2005; Friend, et 
al., 2004; Kagan, et al., 2005; Rhee, et al., 2010;  Schapiro, et al., 2010, and Marcelin, et al., 
2008; all as cited by Johnson, et al., 2010)  
8.1 Newer protease inhibitors 
In the RESIST-1 and RESIST-2 trials (Randomized Evaluation of Strategic Intervention in 
Multidrug Resistant Patients with Tipranavir), tipranavir-ritonavir plus optimized best 
regimen provided superior virologic and immunologic responses over 48 weeks compared 
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with patients who received an investigator-selected ritonavir-boosted comparator PI plus 
optimized background regimen. (Hicks, et al., 2006) Gastrointestinal disorders, 
transaminitis, and hyperlipidemia were more frequent in patients who received tipranavir-
ritonavir compared with the control group. Tipranavir carries black-box warnings regarding 
the risk for hepatitis and hepatic decompensation as well as fatal and non-fatal intracranial 
hemorrhage.  (Aptivus package insert, Boehringer Ingelheim Pharmaceuticals 2008)  
Tipranavir’s unique resistance profile makes it valuable in patients who have failed prior PI-
containing regimens. (Marcelin, et al., 2008)  Tipranavir is approved for highly treatment-
experienced HIV patients or those with multiple PI resistance mutations. 
Ritonavir-boosted darunavir has shown superiority to boosted comparator PIs in treatment-
experienced patients, including those with PI mutations. (Clotet, et al., 2007)  The POWER 1, 
POWER 2, and POWER 3 (Performance Of TMC114/r When evaluated in treatment- 
Experienced patients with PI Resistance) studies found 40%−44% attained viral suppression 
among treatment-experienced patients who had previously failed other PI-based regimens. 
Thus, darunavir is also valuable in patients with significant resistance. (Lefebvre, et al., 
Abstract H-1387, ICAAC 2006)  Darunavir is approved for both treatment-experienced and 
treatment-naïve patients. Table 5 shows the impact of protease mutations on resistance to 
various PIs. 
8.2 New non-NRTI 
The DUET 1 and 2 (TMC125-0216: a phase 3 study to investigate the efficacy, tolerability, and 
safety of TMC125(etravirine) as part of an antiretroviral regimen, with optimized background 
regimen in HIV-1 infected patients with limited to no treatment options) trials examined the 
efficacy of etravirine, a second-generation NNRTI, in treatment-experienced adult patients 
with virological failure on stable antiretroviral therapy and documented genotypic evidence of 
NNRTI resistance, viral load >5000 copies/mL, and ≥3 primary PI mutations.(Lazzarin, et al., 
2007; Madruga, et al., 2007)  Etravirine was associated with superior virologic suppression 
compared with placebo, with up to 62% of patients in the etravirine group achieving 
undetectable viral loads, compared with 44% in the placebo group. (Lazzarin, et al., 2007; 
Madruga, et al., 2007)   Etravirine exhibits retained activity despite multiple NNRTI mutations, 
with high rates of sustained efficacy at 48 weeks in heavily treatment-experienced patients. 
(Haubrich, et al, Abstract #790, CROI 2008; Johnson M, et al., Abstract #792, CROI, 2008)  The 
tolerability profile is comparable to placebo, with the exception of a rash. It is associated with 
significant drug interactions and should not be used with unboosted PIs, boosted atazanavir, 
fosamprenavir, tipranavir, or other NNRTIs.49(Intelence package insert, Tibotech Therapeutics 
2008) The mutation Y181 decreases susceptibility to etravirine, but does not eliminate efficacy 
altogether. (Johnson, et al, 2010; http://aidsinfo.nih.gov) 
8.3 New class: CCR5 antagonist 
Maraviroc, the first drug in this class to be licensed, is active against chemokine receptor R5- 
but not X4-tropic viruses in vitro. In the MOTIVATE 1 and MOTIVATE 2 (Maraviroc versus 
Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients) trials,  
patients who had R5-tropic virus and had been treated with or had resistance to three 
antiretroviral drug classes, and had HIV RNA >5000 copies/mL, demonstrated increased 
CD4+ counts and more sustained viral suppression at 48 weeks following treatment with 
maraviroc compared with placebo, and with  comparable adverse event outcomes. (Gulick, 
et al., 2008)  Maraviroc is not effective in patients with mixed-tropic virus infection; it is 
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indicated for the treatment of patients infected with only CCR5-tropic HIV who are either 
treatment naïve, or who have evidence of viral replication and HIV strains resistant to 
multiple antiretroviral agents.(Selzentry package insert, Pfizer, Inc.)  Patients that may 
benefit from having a regimen including maraviroc can be identified via any of several 
assays available to assess the presence of the CCR5 tropic virus and the minority CXCR4 
(X4) strains.  (Reeves, et al., Abstract H-1026, ICAAC, 2007) 
8.4 New class: Integrase inhibitor 
Raltegravir, the first-in-class integrase inhibitor, was examined in combination with 
optimized background regimen in two identical, placebo-controlled trials in patients 
infected with triple-class drug-resistant HIV-1 in whom antiretroviral therapy had failed. 
(Steigbigel, et al., 2008)  At 48 weeks of therapy, 62.1% and 32.9% of raltegravir and placebo 
patients, respectively, had suppressed HIV RNA viral load. Raltegravir is approved in 
combination with other antiretroviral agents for the treatment of HIV infection in treatment-
naïve or treatment-experienced adult patients who have evidence of viral replication and 
HIV-1 strains resistant to multiple antiretroviral agents. (Isentress package insert, Merck & Co) 
9. Drugs under investigation 
A new integrase inhibitor, Dolutegravir (Glaxo Smith Kline) is in phase 2 clinical trials and 
is active against raltegravir-resistant strains, revealing a higher genetic barrier to resistance 
(Seki, et al., abstract #555, CROI 2010; Eron, et al., abstract #151LB, CROI 2011). 
GSK2248761 is a once daily NNRTI currently in phase 2b studies with activity against virus 
with many NNRTI mutations, including efavirenz resistant strains. (Kim, et al., abstract 
#628, CROI 2011; Kim, et al., abstract #631, CROI 2011)  In addition, this drug appears to 
have an additive to synergistic antiviral effect when coadministered with other 
antiretrovirals. (Vavro, et al. abstract #520, CROI 2011) 
BI-C is a non-cataytic site integrase inhibitor that may have activity against virus resistant to 
other integrase inhibitors. It has shown very good biological and pharmacological profiles 
and is now in Phase 1 clinical trials. (Fenwick, et al., abstract #523, CROI 2011) 
9.1 New classes(future) 
These are not currently approved and have yet to start Phase 3 clinical trials, however, they 
show promise as potential future new drug classes. Their possible addition to the current 
arsenal of antiretrovirals is particularly important for the treatment experienced patient. 
9.1.1 Attachment inhibitors 
Currently in very early trials, this class shows the possibility for potent antiretroviral 
activity against HIV-1 infection. (Nettles, et al., abstract #49, CROI 2011). New targets 
include the gp 120 glycoprotein, which allows attachment of virus to CD4+ cells. (Nowicka-
Sans, et al., abstract #518, CROI 2011) 
9.1.2 Gag inhibitors 
Another potentially new class of antiviral drugs being investigated are gag inhibitors. This 
drug targets the HIV-1 capsid and exhibited inhibition of the early phase of its life cycle. 
(Urano, et al., abstract #525, CROI 2011) 
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 Interactions with other ARVs Selected interactions with  
non-ARV drugs 
Etravirine 
 
Should not be coadministered with: 
 Tipranavir/ritonavir 
 Fosamprenavir/ritonavir 
 Atazanavir/ritonavir 
 Unboosted PIs 
 NNRTIs 
 
Dose adjustment not established with 
Saquinavir, consider Saquinavir 
1000mg bid + Ritonavir 100mg bid 
 
If with Maraviroc: 
MVC 600mg bid 
MVC 150mg bid (if with Ritonavir 
boosted darunavir) 
Drug concentration monitoring 
recommended when used with 
antiarrythmics  
 
INR monitoring recommended when 
used with warfarin;   
clopidogrel should not be coadministered 
 
Certain anticonvulsants, including 
carabamazepine, phenobarbital, and 
phenytoin, can cause significant 
decreases in etravirine plasma 
concentrations  
 
Dose adjustments may be necessary for 
coadministration with itraconazole, 
ketoconazole, voriconazole; coadminister 
with caution and follow drug levels 
 
Clarithromycin alternatives should be 
considered 
 
Rifampin, rifapentine, and rifabutin may 
cause significant decreases in etravirine 
plasma concentrations  
 
Etravirine may increase plasma 
concentrations of diazepam , dose 
adjustment may be necessary 
Dexamethasone should be used with 
caution, as etravirine levels may decrease. 
 
Interaction with certain statins has been 
detected  
 
Etravirine may be coadministered with 
methadone; however, clinical monitoring 
for withdrawal symptoms is 
recommended, as methadone 
maintenance therapy may need to be 
adjusted 
 
Administer with immunosuppressants 
with caution; levels of cyclosporine, 
tacrolimus, and sirolimus may be 
decreased  
Raltegravir No effect expected on the following 
drug classes: PIs, NNRTIs that would 
No effect expected on methadone, opioid 
analgesics, statins, azole antifungals, 
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require dose adjustments 
 
No clinically meaningful effect on 
lamivudine, tenofovir  
 
Recommended dose of raltegravir may 
be coadministered with efavirenz, 
nevirapine  
 
Recommended dose of raltegravir may 
be coadministered with boosted 
tipranavir or atazanavir  
proton pump inhibitors, oral 
contraceptives, anti-erectile dysfunction 
agents 
 
Caution recommended when 
coadministering with rifampin; reduces 
plasma concentrations of raltegravir  
 
Recommended dose of raltegravir may be 
coadministered with rifabutin ;  
recommend 800 mg twice daily with 
coadministered rifampin 
Maraviroc Dose reduction to 150 mg twice daily 
with  PIs (except tipranavir/ritonavir), 
delaviridine  
 
No dose adjustment (300 mg twice 
daily) with tipranavir/ritonavir, 
nevirapine, NRTIs 
 
Dose increase to 600 mg twice daily 
with CYP 3A inducers including 
efavirenz 
 
No effect on zidovudine, lamivudine 
Dose reduction to 150 mg twice daily 
with ketoconazole, itraconazole, 
clarithromycin, other strong CYP 3A 
inhibitors (e.g., nefazadone, 
telithromycin)  
 
Dose increase to 600 mg twice daily with 
CYP 3A inducers including rifampin, 
carbamazepine, phenobarbital, phenytoin 
 
No clinically relevant effect on 
midazolam, oral contraceptives 
(ethinylestradiol and levonorgestrel)  
Table 6. Drug Interactions of Newly Approved Antiretroviral Therapies  
ARV, antiretroviral; INR, International Normalized Ratio; CYP, cytochrome; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; 
PI, protease inhibitor. 
(Aptivus, Invirase, Isentress, Kaletra, Lexiva, Prezista, Reyataz, Selzentry, Sustiva, Viracept, 
and Viramune prescribing information) 
10. Conclusion 
Managing treatment-experienced patients poses considerable challenges, not the least of 
which includes selecting appropriate therapy to maximize clinical benefit, minimize 
toxicities, and avoid drug-drug interactions. The best approach to these patients is 
preventative. As noted above, with appropriate attention to medication adherence and 
addressing the side effects and toxicities of antiretroviral medications proactively, many 
patients can remain on the first regimen for many years. In the real world, however, a 
substantial proportion of patients fail to adhere to their medication. Many suffer from overt 
toxicities and/or minor/cosmetic side effects that affect compliance with treatment and 
eventually necessitate a switch in regimen. Given the broad spectrum of available agents—
including the recent advent of two entirely new classes of antiretroviral agents—the 
majority of patients have reasonably well-tolerated therapeutic options that, with 
appropriate attention to all aspects of the clinical and patient experience, can provide 
sufficient long-term efficacy which has transformed HIV from an inevitably fatal disease to 
one that can truly be considered a chronic condition.  
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book. This 27-chapter Open Access book well covers HIV/AIDS translational researches on pathogenesis,
diagnosis, treatment, prevention, and also those beyond conventional fields. These are by no means inclusive,
but they do offer a good foundation for the development of clinical patient care. The translational model forms
the basis for progressing HIV/AIDS clinical research. When linked to the care of the patients, translational
researches should result in a direct benefit for HIV/AIDS patients.
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